BDSX vs GH
BDSX: Biodesix develops precision diagnostic tests powered by molecular and AI analysis to guide oncology treatment decisions for clinicians, payers, and biopharmaceutical companies. GH: Guardant Health is a precision oncology company transforming cancer care with FDA-approved blood and tissue tests powered by AI analytics that span early detection, treatment selection, and disease monitoring.
Side-by-side fundamentals
| Metric | BDSX | GH | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $21.39 | $150.75 | |
| Market cap as of 2026-07-23 | $222M | $19.8B | |
| PEG as of 2026-07-23 | n/a | -71.05 | |
| Net margin as of 2026-07-23 | -33.3% | -40.1% | BDSX higher |
| Gross margin as of 2026-07-23 | +82.1% | +64.9% | BDSX higher |
| Operating margin as of 2026-07-23 | -25.9% | -42.7% | BDSX higher |
| ROE as of 2026-07-23 | -375.1% | -246.6% | GH higher |
| ROA as of 2026-07-23 | -35.6% | -26.5% | GH higher |
| Debt / equity as of 2026-07-23 | 5.09 | 16.78 | BDSX lower |
| Revenue growth (YoY) as of 2026-07-23 | +29.1% | +39.6% | GH higher |
| Revenue CAGR (3y) SEC XBRL | +32.3% | +29.8% | BDSX higher |
| Beta as of 2026-07-23 | 0.58 | 1.63 | |
| 1-year return as of 2026-07-22 close | +202.0% | +225.9% | GH higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.